Literature DB >> 22577174

ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation.

Sabrina Weissmüller1, Linda Y Semmler, Ulrich Kalinke, Stefan Christians, Jan Müller-Berghaus, Zoe Waibler.   

Abstract

TGN1412, a superagonistic CD28-specific antibody, was shown to require Fc-cross-linking or immobilization as a prerequisite to mediate T-cell proliferation and cytokine release in vitro. We used primary human umbilical vein endothelial cells (HUVECs) to study their ability to induce activation of TGN1412-treated T cells. We confirmed that peripheral primary human T cells do not show activation upon stimulation with soluble TGN1412 alone. Nevertheless, cocultivation of TGN1412-treated T cells with HUVECs induced T-cell activation that was further enhanced using cytokine prestimulated HUVECs. Unexpectedly, Fc-FcγR interaction was dispensable for endothelial cell-mediated proliferation of TGN1412-treated T cells. Transwell-culture assays showed that TGN1412-treated T cells need direct cell-to-cell contact to HUVECs to induce proliferation. We found that costimulatory ICOS-LICOS interaction between T cells and endothelial cells is critically involved in TGN1412-mediated effects. Blocking LICOS reduced TGN1412-mediated T-cell proliferation significantly, whereas recombinant LICOS fully conferred TGN1412-mediated T-cell proliferation. Of note, cytokine stimulation enhanced LICOS expression on HUVECs and ICOS-LICOS interaction up-regulated ICOS expression on TGN1412-treated T cells. Hence, we provide a model of positive feedback conferred by ICOS-LICOS interaction between TGN1412-treated T cells and endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22577174     DOI: 10.1182/blood-2011-12-401083

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus.

Authors:  Vivian A Scheuplein; Janna Seifried; Anna H Malczyk; Lilija Miller; Lena Höcker; Júlia Vergara-Alert; Olga Dolnik; Florian Zielecki; Björn Becker; Ingo Spreitzer; Renate König; Stephan Becker; Zoe Waibler; Michael D Mühlebach
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

2.  Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.

Authors:  Nicolas Poirier; Caroline Mary; Stephanie Le Bas-Bernardet; Veronique Daguin; Lyssia Belarif; Melanie Chevalier; Jeremy Hervouet; David Minault; Simon Ville; Vianney Charpy; Gilles Blancho; Bernard Vanhove
Journal:  MAbs       Date:  2014-03-05       Impact factor: 5.857

3.  Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.

Authors:  David Eastwood; Chris Bird; Paula Dilger; Jason Hockley; Lucy Findlay; Stephen Poole; Susan J Thorpe; Meenu Wadhwa; Robin Thorpe; Richard Stebbings
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

4.  TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model.

Authors:  Sabrina Weißmüller; Stefanie Kronhart; Dorothea Kreuz; Barbara Schnierle; Ulrich Kalinke; Jörg Kirberg; Kay-Martin Hanschmann; Zoe Waibler
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

5.  Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect Leishmania Infection of Human Macrophages.

Authors:  Katharina Arens; Christodoulos Filippis; Helen Kleinfelder; Arthur Goetzee; Gabriele Reichmann; Peter Crauwels; Zoe Waibler; Katrin Bagola; Ger van Zandbergen
Journal:  Front Immunol       Date:  2018-07-31       Impact factor: 7.561

6.  Reduced Expression of Autophagy Markers and Expansion of Myeloid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe COVID-19 Patients.

Authors:  Sergej Tomić; Jelena Đokić; Dejan Stevanović; Nataša Ilić; Alisa Gruden-Movsesijan; Miroslav Dinić; Dušan Radojević; Marina Bekić; Nebojša Mitrović; Ratko Tomašević; Dragan Mikić; Dragoš Stojanović; Miodrag Čolić
Journal:  Front Immunol       Date:  2021-02-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.